Alector, Inc. income statement ALEC

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Alector, Inc. reported revenue of $21.0 million, down 79.1% from the year before. It recorded a net loss of $142.9 million. The operating loss came to $156.0 million, an operating margin of -741.3%. Diluted earnings per share were -$1.39. Over the twelve months ended Sep 30, 2026, revenue was $173.5 million and net income was $41.4 million. Across the 7 fiscal years shown, revenue shrank from $21.2 million in fiscal 2019 to $21.0 million in fiscal 2025, about 0.1% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019
Revenue	173 +151.2%	21 -79.1%	101 +3.6%	97 -27.4%	134 -35.5%	207 +881.5%	21 -0.6%	21
Research and development	100 -27.2%	123 -33.8%	186 -3.2%	192 -8.7%	210 +11.1%	189 +20.7%	157 +56.0%	101
Selling, general and administrative	39 -30.5%	54 -9.4%	60 +5.2%	57 -7.1%	61 +10.9%	55 -7.3%	59 +69.3%	35
Restructuring and impairment	—	2 -41.0%	4 +129.4%	2	—	—	—	—
Operating income	35 +128.3%	-156 -7.6%	-145 +4.4%	-152 -10.1%	-138 -268.9%	-37 +80.9%	-195 -70.6%	-114
Other non-operating income (expense)	7 -57.5%	13 -49.2%	26 -1.8%	27 +241.5%	8 +654.4%	1 -79.2%	5 -45.2%	9
Pretax income	42	-143 -20.0%	-119	—	—	—	—	—
Income tax	0 +645.8%	0 +31.2%	0 -97.5%	5 +60.2%	3	0	—	—
Net income	41 +138.4%	-143 -20.1%	-119 +8.7%	-130 +2.2%	-133 -267.0%	-36 +80.9%	-190 -80.5%	-105
Basic EPS	0.37 +134.8%	-1.39 -13.0%	-1.23 +21.2%	-1.56 +3.7%	-1.62	—	—	—
Diluted EPS	0.37 +134.6%	-1.39 -13.0%	-1.23 +21.2%	-1.56 +3.7%	-1.62	—	—	—
Weighted average shares, basic	111 +10.6%	103 +6.6%	97 +15.4%	84 +1.5%	82	—	—	—
Weighted average shares, diluted	111 +11.2%	103 +6.6%	97 +15.4%	84 +1.5%	82	—	—	—
Other measures
Depreciation and amortization	4 -26.1%	6 +5.8%	5 -5.6%	6 +0.2%	6 -9.7%	6 +7.8%	6 +55.5%	4
EBITDA	39 +133.3%	-150 -7.7%	-140 +4.4%	-146 -10.5%	-132 -325.8%	-31 +83.6%	-189 -71.1%	-111
Margins
Operating margin	20.16%	-741.30%	-144.19%	-156.33%	-103.16%	-18.04%	-925.08%	-539.16%
Pretax margin	24.08%	-678.36%	-118.26%	—	—	—	—	—
Profit margin	23.87%	-679.16%	-118.39%	-134.34%	-99.77%	-17.54%	-901.64%	-496.65%
EBITDA margin	22.62%	-714.13%	-138.82%	-150.43%	-98.88%	-14.98%	-897.26%	-521.37%
Effective tax rate	0.86%	—	—	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: ALEC (Nasdaq)
Fiscal year ends: December 31
Headquarters: South San Francisco, CA
SEC filer status: Accelerated filer, Smaller reporting company
SEC CIK: 1653087
Former names: Alector LLC (until Sep 16, 2015)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.